Bruker Unveils MyGenius PRO Diagnostics System

Why It Matters

MyGenius PRO speeds infectious‑disease diagnostics, boosting lab efficiency and capacity at a time of rising demand for rapid testing of vulnerable patients. Its automated workflow and expanding assay portfolio position Bruker as a stronger competitor in the European molecular diagnostics market.

Key Takeaways

• MyGenius PRO automates sample-to-answer workflow for infectious disease testing
• Initial IVDR menu includes CMV, EBV, and BK virus assays
• System already deployed at a European transplant centre for routine testing
• Future expansions will add HIV, HBV, HCV, and HHV‑6 assays

Pulse Analysis

Bruker’s entry into the European automated molecular diagnostics arena reflects a broader industry shift toward high‑throughput, sample‑to‑answer platforms. By integrating PCR technology with continuous loading and random‑access capabilities, MyGenius PRO addresses the bottlenecks that traditional batch testing creates, especially in hospitals handling large volumes of infectious disease specimens. The system’s design aligns with the European In‑Vitro Diagnostic Regulation (IVDR), ensuring compliance while delivering rapid, reliable results for clinicians.

The initial assay menu—targeting cytomegalovirus, Epstein‑Barr virus, and BK virus—focuses on immunocompromised populations such as transplant recipients, where early detection is critical. Automating the entire workflow reduces hands‑on time, minimizes contamination risk, and accelerates turnaround, enabling labs to increase testing capacity without proportional staffing growth. Early adoption at a European transplant centre demonstrates real‑world utility, and the planned addition of HIV‑1, hepatitis B and C, and HHV‑6 assays will broaden the platform’s clinical relevance across infectious disease specialties.

Strategically, the launch leverages Bruker’s partnership with ELITechGroup and Hitachi High‑Tech, blending assay expertise with advanced engineering. This collaboration not only accelerates product development but also opens pathways to Asian markets, where Hitachi will market the system as Labospect GA‑5. Coupled with Bruker’s recent $500 million MRI superconductor agreements, the MyGenius PRO rollout signals a diversified growth strategy, positioning the company to capture a larger share of the lucrative European molecular diagnostics market while reinforcing its global brand as a leader in analytical technologies.